Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.21 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +449.98 (+1.18%)
     

  • CAD/USD

    0.7309
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    78.57
    +0.46 (+0.59%)
     

  • Bitcoin CAD

    87,310.52
    +115.71 (+0.13%)
     

  • CMC Crypto 200

    1,326.14
    +49.16 (+3.85%)
     

  • GOLD FUTURES

    2,310.10
    +1.50 (+0.06%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ futures

    18,036.75
    +36.00 (+0.20%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • CAD/EUR

    0.6788
    -0.0029 (-0.43%)
     

Carisma Therapeutics to Present at Upcoming Conferences

PR Newswire
·1 min read

PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences:

(PRNewsfoto/CARISMA Therapeutics Inc.)
(PRNewsfoto/CARISMA Therapeutics Inc.)

Needham 23rd Annual Virtual Healthcare Conference

  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.

  • Wednesday, April 10 at 3:45 PM ET

  • Virtual

Chardan 8th Annual Genetic Medicines & Cell Therapy Manufacturing Summit

  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.

  • Monday, April 29 at 2:00 PM ET

  • Virtual

ADVERTISEMENT

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following each event.

About Carisma 

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-conferences-302106448.html

SOURCE Carisma Therapeutics Inc.